Icelandic Biotech Company Alvotech to Explore Listing in Stockholm

Dow Jones

03-20

By Dominic Chopping

Icelandic biotechnology company Alvotech intends to explore the possibility of a Stockholm listing as it announced the acquisition of a Swedish research and development operation and drug candidate.

Alvotech said Thursday that it will pay 275 million Swedish kronor ($27.2 million) for Xbrane Biopharma's research and development operations outside of Stockholm and its XB003 drug that is being developed as an anti-inflammation treatment for rheumatoid arthritis and psoriasis patients.

The acquired research and development site will become Alvotech's Swedish base of operations, it said.

Alvotech shares are listed in Iceland and the U.S. and it said it will also explore a possible listing of Swedish Depository Receipts in Stockholm in the future.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

March 20, 2025 09:16 ET (13:16 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2520451709"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520451709\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2520451709?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-20 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520451709","market":"sh","top_or_hot":-1,"title":"Icelandic Biotech Company Alvotech to Explore Listing in Stockholm","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre>\n \n</pre>\n<p>\n  Icelandic biotechnology company <a href=\"https://laohu8.com/S/ALVO\">Alvotech</a> intends to explore the possibility of a Stockholm listing as it announced the acquisition of a Swedish research and development operation and drug candidate. \n</p>\n<p>\n  Alvotech said Thursday that it will pay 275 million Swedish kronor ($27.2 million) for Xbrane Biopharma's research and development operations outside of Stockholm and its XB003 drug that is being developed as an anti-inflammation treatment for rheumatoid arthritis and psoriasis patients. \n</p>\n<p>\n  The acquired research and development site will become Alvotech's Swedish base of operations, it said. \n</p>\n<p>\n  Alvotech shares are listed in Iceland and the U.S. and it said it will also explore a possible listing of Swedish Depository Receipts in Stockholm in the future. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 20, 2025 09:16 ET (13:16 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Icelandic Biotech Company Alvotech to Explore Listing in Stockholm</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIcelandic Biotech Company Alvotech to Explore Listing in Stockholm\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-20 21:16</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dominic Chopping \n</p>\n<pre>\n \n</pre>\n<p>\n  Icelandic biotechnology company <a href=\"https://laohu8.com/S/ALVO\">Alvotech</a> intends to explore the possibility of a Stockholm listing as it announced the acquisition of a Swedish research and development operation and drug candidate. \n</p>\n<p>\n  Alvotech said Thursday that it will pay 275 million Swedish kronor ($27.2 million) for Xbrane Biopharma's research and development operations outside of Stockholm and its XB003 drug that is being developed as an anti-inflammation treatment for rheumatoid arthritis and psoriasis patients. \n</p>\n<p>\n  The acquired research and development site will become Alvotech's Swedish base of operations, it said. \n</p>\n<p>\n  Alvotech shares are listed in Iceland and the U.S. and it said it will also explore a possible listing of Swedish Depository Receipts in Stockholm in the future. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 20, 2025 09:16 ET (13:16 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALVO","symbol_name":"Alvotech","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2520451709","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520451709","pubTimestamp":1742476560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Icelandic biotechnology company Alvotech intends to explore the possibility of a Stockholm listing as it announced the acquisition of a Swedish research and development operation and drug candidate.Alvotech said Thursday that it will pay 275 million Swedish kronor  for Xbrane Biopharma's research and development operations outside of Stockholm and its XB003 drug that is being developed as an anti-inflammation treatment for rheumatoid arthritis and psoriasis patients.The acquired research and development site will become Alvotech's Swedish base of operations, it said.Alvotech shares are listed in Iceland and the U.S. and it said it will also explore a possible listing of Swedish Depository Receipts in Stockholm in the future.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALVO":"Alvotech","BK4139":"生物科技"},"translate_title":"冰岛生物技术公司Alvotech将探索在斯德哥尔摩上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALVO":1},"content_text":"By Dominic Chopping \n\n\n \n\n\n  Icelandic biotechnology company Alvotech intends to explore the possibility of a Stockholm listing as it announced the acquisition of a Swedish research and development operation and drug candidate. \n\n\n  Alvotech said Thursday that it will pay 275 million Swedish kronor ($27.2 million) for Xbrane Biopharma's research and development operations outside of Stockholm and its XB003 drug that is being developed as an anti-inflammation treatment for rheumatoid arthritis and psoriasis patients. \n\n\n  The acquired research and development site will become Alvotech's Swedish base of operations, it said. \n\n\n  Alvotech shares are listed in Iceland and the U.S. and it said it will also explore a possible listing of Swedish Depository Receipts in Stockholm in the future. \n\n\n \n\n\n  Write to Dominic Chopping at dominic.chopping@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 09:16 ET (13:16 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}